Trial Profile
A Phase II Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients: Big Ten Cancer Research Consortium BTCRC-BRE16-042
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Jul 2023
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- 03 Jul 2023 Status changed from recruiting to active, no longer recruiting.
- 18 Jan 2023 Planned End Date changed from 1 Jan 2024 to 1 Sep 2024.
- 18 Jan 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Sep 2023.